Brian Hill, MD, PhD, Cleveland Clinic

Dr. Hill and Dr. Sauter Consider CAR T-Cell Therapy in Second-Line Setting for DLBCL

November 2nd 2022

Craig Sauter, MD, and Brian T. Hill, MD, PhD, consider CAR T-cell therapy in the second-line setting for patients with diffuse large B-cell lymphoma.

Cleveland Clinic Experts Assess Strategies to Accelerate CAR T-Cell Production

November 2nd 2022

Craig Sauter, MD, and Brian T. Hill, MD, PhD, discuss recent data showing that the CAR T-cell production can be shortened.

Dr. Hill and Dr. Sauter Discuss the Future of CAR T-Cell Products Agents in Lymphoma

November 2nd 2022

Craig Sauter, MD, and Brian T. Hill, MD, PhD, discuss potential directions for CAR T-cell therapy in lymphomas.

Cleveland Clinic Experts Discuss the Potential for Allogeneic CAR T-Cell Agents

November 2nd 2022

Brian T. Hill, MD, PhD, and Craig Sauter, MD, discuss the promise of allogeneic CAR T-cell products.

Dr. Hill and Dr. Sauter Address Financial Toxicity in CAR T-Cell Therapy

November 2nd 2022

Craig Sauter, MD, and Brian T. Hill, MD, PhD, address the issue of financial toxicity in CAR T-cell therapy.

test time jump

December 7th 2020

Brian T. Hill, MD, PhD, discusses ​the safety profiles of BTK inhibitors in mantle cell lymphoma.

Dr. Hill on the Safety Profiles of BTK Inhibitors in MCL

December 7th 2020

Brian T. Hill, MD, PhD, discusses ​the safety profiles of BTK inhibitors in mantle cell lymphoma.

Novel Therapies: R2-GDP-GOTEL and Smart Start

July 17th 2020

Novel Treatment Combinations for R/R DLBCL

July 17th 2020

Relapsed/Refractory DLBCL: Unmet Needs

July 17th 2020

Emerging Treatments for Relapsed/Refractory DLBCL

July 17th 2020

SADAL Trial Regimen FDA Approval

July 17th 2020

SADAL Trial Overview

July 17th 2020

CAR T-Cell Therapy Clinical Trials

July 17th 2020

CAR T-Cell Therapy Response Rates

July 17th 2020

CAR T Cell Therapy in Relapsed/Refractory DLBCL

July 17th 2020

Relapsed/Refractory DLBCL Treatment Landscape

July 17th 2020

R/R DLBCL: Transplant Eligibility and R-CHOP

July 17th 2020

Newly Diagnosed DLBCL: Treatment Decision Factors

July 17th 2020

DLBCL Risk Assessment and Genetic Signatures

July 17th 2020